中文

万泰生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-28
ItemAmountY/Y
Revenue¥0.52B+30.6%
Gross profit¥0.37B
Operating income¥-0.06B
Net income¥-0.04B
Gross margin69.9%Net margin -8.6%
Revenue Q/Q+63.2%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.16B30.1%
R&D¥0.11B21.0%
SG&A¥0.24B45.9%
Tax & other¥-0.01B-2.6%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

豪威集团华友钴业瑞芯微兆易创新洛阳钼业德业股份东鹏饮料澜起科技中国通号中微公司传音控股海光信息

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies